PV Bulletin

MHRA: Updated information on the MHRA's service providing scientific and regulatory guidance to developers of innovative medical products

Guidance for innovators and developers on accessing regulatory support and scientific expertise.

Primary source: Medicines and Healthcare products Regulatory Agency (MHRA)

PV Impact Brief

MonitoringConfidence: high

What changed

Updated guidance on the MHRA Innovation Accelerator, emphasizing access to regulatory support and scientific expertise for early-stage engagement with the regulator.

Why it matters

This initiative allows innovators and developers to engage proactively with MHRA on pharmacovigilance planning and risk management, potentially improving product safety and regulatory adherence early in development.

Action needed

Innovators must now utilize the Innovation Accelerator for access to regulatory expertise and guidance on pharmacovigilance and risk management strategies.

Relevant for
Regulatory Intelligence LeadQPPV
Processes impacted
Country Compliance
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Guidance
Policy status
revised
Publication date
2026-06-29
Policy change
Updated information on the MHRA's service providing scientific and regulatory guidance to developers of innovative medical products.

Key changes

Consolidated pathway for early-stage engagement with the regulator for innovative medicines and medical devices, focusing on scientific and regulatory advice.

Affected workflows

Country Compliance

Responsible groups

Clinical DevelopmentSafety TeamsRegulatory Affairs

PV impact

Facilitates proactive discussion with regulators on pharmacovigilance planning and risk management strategies early in the product development lifecycle for innovative products.

View regulator source

Source document details

Exact policy details

Innovation Accelerator Access
Access to MHRA scientific expertise and regulatory guidance
Applies to: Innovators and developers of innovative products
The Innovation Accelerator provides innovators and developers of innovative products access to MHRA scientific expertise, regulatory guidance and an enhanced advice and signposting service. · p. 1 · High · Source
Supporting ILAP
Supports the delivery of the Innovative Licensing and Access Pathway (ILAP)
Applies to: Part of the regulatory framework for innovative medical products
It also supports the delivery of the Innovative Licensing and Access Pathway (ILAP). · p. 1 · High · Source

Extracted documents

Evidence and confidence

Confidence: highSource updated: Jun 29, 2026

Full briefing

Practical implication

Innovators must now utilize the Innovation Accelerator for access to regulatory expertise and guidance on pharmacovigilance and risk management strategies.

The MHRA Innovation Accelerator provides a consolidated pathway for early-stage engagement with the regulator and offers scientific and regulatory guidance to developers of innovative medical products, facilitating discussion on pharmacovigilance and risk management strategies.

What changed: Updated guidance on the MHRA Innovation Accelerator, emphasizing access to regulatory support and scientific expertise for early-stage engagement with the regulator.

Why it matters: This initiative allows innovators and developers to engage proactively with MHRA on pharmacovigilance planning and risk management, potentially improving product safety and regulatory adherence early in development.

Practical implication: Innovators must now utilize the Innovation Accelerator for access to regulatory expertise and guidance on pharmacovigilance and risk management strategies.

View original source

Published from the Firecrawl policy change extraction pipeline.

#Safety Signals#Medicines and Healthcare products Regulatory Agency (MHRA)#United Kingdom#guidance#Revised#policy-change#firecrawl-policy-agent

Related updates for your role

publicTherapeutics Goods Administration · Australia · Updated Jul 20, 2026

Updates on ISO 14155 and N=1 Therapeutics Discussed by TGA

Urgency: High

Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.

Inspection ReadinessICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicMedicines and Healthcare products Regulatory Agency (MHRA) · United Kingdom · Updated May 23, 2026

MHRA confirms UK clinical trial safety reporting guidance is effective

Urgency: High

Safety lead to: (1) perform a UK-clinical-trial safety reporting gap assessment against MHRA’s effective guidance sections (MedDRA coding; AE/SAE; RSI governance; SUSARs; annual safety reporting; USMs; serious breaches; temporary suspension), (2) update controlled SOPs/WIs and training records to reflect “effective” status as of 28 Apr 2026, and (3) document deviations/gaps and open CAPA where needed for ongoing UK trials and new submissions.

ICSRCountry ComplianceRegulatory Intelligence Lead
SOP Impact4 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Guidance
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Jul 20, 2026

CHMP Draft Agenda for Public Consultation on Thalassaemia and Sickle Cell Disease Guidelines

Urgency: High

Sponsors and MAHs must review and align safety data collection and reporting protocols with the newly adopted guidelines while preparing for implementation of PRAC recommendations stemming from this meeting.

Signal ManagementICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Agenda
Read impact briefarrow_forward
publicSwissmedic · Switzerland · Updated Jul 17, 2026

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Urgency: High

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Checklist
Read impact briefarrow_forward